The authors reported a decrease in global m6A methylation within skeletal muscle from hSOD1G93A transgenic ALS mice. They also observed reduced expression of the m6A methyltransferase METTL3 in the same tissue. These changes in the RNA modification landscape were presented as muscle-intrinsic molecular alterations accompanying the ALS phenotype. The preprint did not provide cohort sizes, quantification thresholds, or exact assay conditions in the abstract; those methodological specifics are not reported there.
Multi-omics analyses, as described by the study team, connected m6A perturbation with impaired triglyceride metabolism in ALS skeletal muscle. The investigators reported metabolic signatures and pathway-level associations consistent with defective lipid handling in the affected muscle. The abstract does not list the specific omics platforms, normalization approaches, or statistical cutoffs used for pathway mapping; those experimental details are absent from the provided source text.
In cultured ALS myotubes, the authors tested the functional role of METTL3. They found that METTL3 promotes triglyceride accumulation through an m6A-dependent mechanism. Overexpressing METTL3 in these myotubes reportedly improved cellular energy supply and alleviated features of muscle atrophy. The study team framed this as a cell-autonomous effect, linking restored lipid storage to improved myotube physiology. Specific transfection or viral delivery methods, expression fold-changes, and time courses were not reported in the abstract, so those procedural details remain unspecified in the source.
The group extended their work to an in vivo ALS model. Muscle-targeted overexpression of Mettl3 was associated with attenuation of skeletal muscle atrophy, improved motor performance, and prolonged survival of the ALS mice, according to the preprint. Those reported outcomes indicate that manipulating the m6A writer in muscle produced measurable organism-level benefits in this transgenic model. The abstract does not disclose delivery vectors, dosing regimens, the age at intervention, nor quantitative survival statistics; such methodological and numerical parameters are not provided in the source abstract.
Mechanistic experiments identified the fatty acid activation enzyme ACSL1 as a key downstream effector of METTL3 in skeletal muscle. Data indicated that METTL3-mediated m6A modification enhances Acsl1 mRNA stability, which in turn increases ACSL1 expression and supports triglyceride metabolism. The authors further reported that the m6A reader protein IGF2BP2 is required for this regulatory effect on Acsl1 expression, placing IGF2BP2 as the mediator linking m6A marks to mRNA stability in this axis. The abstract does not enumerate the assays (for example, specific RNA stability assays, reporter constructs, or binding studies) used to establish these interactions; those experiment-level descriptions are not included in the provided text.
This article is a preprint and has not been peer reviewed, a fact the authors and the hosting platform explicitly state. The abstract omits several key experimental details that readers and clinicians would normally seek before evaluating translational potential: sample sizes, statistical measures, precise experimental conditions for in vitro and in vivo manipulations, vector and dose information for Mettl3 overexpression, and quantitative survival or motor-performance data. The functional link between restored triglyceride accumulation and long-term muscle function in human ALS patients remains untested by this report. The authors did not report any clinical or human tissue validation within the abstract. Future steps implied but not documented in the source include independent replication, peer review, and detailed methodological disclosure prior to considering clinical translation or therapeutic targeting of METTL3, m6A, or ACSL1 in ALS.
Funding and disclosure: The preprint lists national and provincial Chinese funding sources and a local development plan; the authors declared no competing interests. Those statements appear in the source metadata. Because the work remains unrefereed, readers should treat the findings as preliminary until full peer review and methodological details are available.